Shah Sudhir V, Rajapurkar Mohan M
Division of Nephrology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Hemoglobin. 2009;33(5):378-85. doi: 10.3109/03630260903212233.
There are two major forms of kidney disease: acute renal failure [also referred to as acute kidney injury (AKI)] and chronic kidney disease (CKD). Acute renal failure is an abrupt loss of kidney function within 48 h, whereas CKD is a loss of kidney function greater than 3 months. There is a large amount of experimental evidence for an increase of labile iron in a wide variety of models of kidney disease. Additionally, iron chelators provide protection, indicating an important role of labile iron in these diseases. These observations suggest that iron chelators may provide a new modality of prevention and treatment of kidney disease.
急性肾衰竭[也称为急性肾损伤(AKI)]和慢性肾脏病(CKD)。急性肾衰竭是指在48小时内肾功能突然丧失,而慢性肾脏病是指肾功能丧失超过3个月。在多种肾脏疾病模型中,有大量实验证据表明不稳定铁增加。此外,铁螯合剂具有保护作用,表明不稳定铁在这些疾病中起重要作用。这些观察结果表明,铁螯合剂可能为肾脏疾病的预防和治疗提供一种新的方式。